Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer

Çalışkan, Müjgan; Türkeri, Levent; Mansuroğlu, Banu; Toktaş, Gökhan; Aksoy, Bülent Arman; Ünlüer, Erol Erden; Akdaş, Atıf

doi:10.1046/j.1464-410x.1997.06911.x

Cited by 36 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Altered expression of p53 was found in 53% of our patients. In previous studies with Ta or T1 BC, altered expression of p53 was reported to be 34% to 65%, though [34]. However, other investigators did not find such findings [20,30,35].…”

Section: Discussionmentioning

confidence: 88%

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Park

Song

Shin

et al. 2013

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Park

Song

Shin

et al. 2013

Urologic Oncology: Seminars and Original Investigations

View full text Add to dashboard Cite

“…Although several investigators found a correlation [39,40] , others [41][42][43] have concluded that p53 overexpression does not affect survival in patients undergoing cystectomy for locally advanced cancer. The clinical status of invasive tumors related to other independent prognostic factors such as stage, grade, multifocality, or carcinoma in situ.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of p53 Nuclear Accumulation in Low- and High-Grade (WHO/ISUP Classification) Transitional Papillary Carcinomas of the Bladder for Tumor Recurrence and Progression

Vardar¹,

Günlüsoy²,

Minareci³

et al. 2006

Urol Int

View full text Add to dashboard Cite

Objectives: To evaluate the association of p53 nuclear accumulation with recurrence and progression in transitional cell carcinomas of the bladder and to examine the distribution of p53 in low-grade and high-grade transitional cell carcinomas according to the World Health Organization/International Society of Urological Pathology classification. Patients and Methods: Nuclear accumulations of p53 were examined in a total of 99 patients with transitional cell carcinoma between May 1995 and October 1999. The mean age was 64 years. There were 94 (95%) men and 5 (5%) women. Following resection, surgical specimens were examined, and p53 accumulation with a 20% cutoff value was accepted as positive staining. Of the 99 patients, 52 (53%) had histologically superficial bladder tumors, and 47 (47%) had invasive tumors. Data concerning grade, stage, number of recurrences, and disease progression were available for each patient. Results: The median follow-up period was 55 months. 60 of the 99 patients (61%) had p53 overexpression. The difference for p53 overexpression between low-grade and high-grade tumors was significant (p < 0.05). In low- and high-grade tumors, there was no significant relationship for recurrence between p53-positive and p53-negative groups. But there was a statistically significant relationship between progression and histological grade of the tumors. p53 had no significant relationship with tumor recurrences (p > 0.05), but its relationship with progression was statistically significant (p < 0.05). Conclusions: We did not find a correlation between tumor recurrence and p53 overexpression, but p53 overexpression has a predictive value in determining tumor progression. High-grade tumors had higher p53-positive values than low-grade tumors. This group of patients should be considered for radical therapies on the basis of other prognostic parameters.

show abstract

“…These markers include the expression of oncogenes, tumor suppressor genes, cell cycle regulators, growth factors, and cell adhesion molecules [103][104][105][106]. The principle of gene expression profile analysis.…”

Section: Proteomics and Protein Expression Alterationsmentioning

confidence: 99%

Bladder cancer: translating molecular genetic insights into clinical practice

Liu¹,

Zhang²,

MacLennan³

et al. 2011

Human Pathology

168

124

View full text Add to dashboard Cite

Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer

Cited by 36 publications

References 5 publications

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?

Evaluation of p53 Nuclear Accumulation in Low- and High-Grade (WHO/ISUP Classification) Transitional Papillary Carcinomas of the Bladder for Tumor Recurrence and Progression

Bladder cancer: translating molecular genetic insights into clinical practice

Contact Info

Product

Resources

About